SCHEMBL4673364

SCHEMBL4673364

O=C(Cc1cc(S(=O)(=O)c2ccc(F)cc2)c[nH]1)C(=O)c1nc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTR2A P28223 4/20 0.33
KCNH2 Q12809 4/20 0.33
HTR2C P28335 2/20 0.33
AKR1B1 P15121 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NAMPT P43490 3/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP9 P14780 1/20 0.31
MMP12 P39900 1/20 0.31
MMP13 P45452 1/20 0.31
MMP14 P50281 1/20 0.31
CFTR P13569 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677297 0.90 ALDH1A1 (0.35) HTR2AALDH1A1NAMPTPTGER3
SCHEMBL4674944 0.89 ALDH1A1 (0.36) SMN1; SMN2HTTAKR1B1ALDH1A1MEN1
SCHEMBL4678791 0.82 RORC (0.35) HTR2AKCNH2HTR2CAKR1B1NAMPT
SCHEMBL4671870 0.81 LMNA (0.34) SMN1; SMN2LMNAHTTKDM4EHTR2A
SCHEMBL4677905 0.81 ALDH1A1 (0.33) SMN1; SMN2LMNAHTTKDM4EHTR2A
SCHEMBL4675404 0.81 LMNA (0.34) LMNAKMT2AMAPT
SCHEMBL4674792 0.79 LOX (0.33) HTR2AKCNH2HTR2CAKR1B1ALDH1A1
SCHEMBL4674484 0.79 NAMPT (0.35) SMN1; SMN2LMNAHTTKDM4EHTR2A
SCHEMBL4680396 0.79 MMP1 (0.39) SMN1; SMN2LMNAHTTKDM4EHTR2A
SCHEMBL4677764 0.78 LOX (0.39) SMN1; SMN2HTR2AKCNH2HTR2CCFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SMN1; SMN2 4107/4885LMNA 659/4885HTT 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.